Repligen Corporation (NASDAQ:RGEN) – Equities researchers at William Blair cut their FY2020 earnings per share (EPS) estimates for Repligen Corporation in a report released on Monday. William Blair analyst A. Murphy now forecasts that the biotechnology company will post earnings of $1.08 per share for the year, down from their prior forecast of $1.10. William Blair currently has a “Outperform” rating on the stock.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The business had revenue of $32.40 million for the quarter, compared to analysts’ expectations of $31.72 million. During the same period last year, the business earned $0.16 EPS. The company’s revenue was up 11.0% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: This article was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/repligen-corporation-expected-to-post-fy2020-earnings-of-1-08-per-share-rgen/1468719.html.

RGEN has been the subject of a number of other reports. First Analysis reaffirmed an “equal weight” rating and issued a $40.00 price target on shares of Repligen Corporation in a report on Friday, April 21st. BidaskClub downgraded Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Jefferies Group LLC reissued a “hold” rating and issued a $40.00 price objective (up from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Zacks Investment Research downgraded Repligen Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, Janney Montgomery Scott increased their price objective on Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Repligen Corporation has a consensus rating of “Buy” and an average target price of $41.20.

Repligen Corporation (NASDAQ RGEN) traded down 3.54% during mid-day trading on Thursday, hitting $41.20. 119,542 shares of the stock were exchanged. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The company has a 50 day moving average of $41.84 and a 200 day moving average of $36.52. The firm has a market cap of $1.54 billion, a P/E ratio of 80.63 and a beta of 1.30.

Several large investors have recently added to or reduced their stakes in RGEN. BlackRock Inc. boosted its stake in Repligen Corporation by 143,196.5% in the first quarter. BlackRock Inc. now owns 4,664,302 shares of the biotechnology company’s stock valued at $164,187,000 after buying an additional 4,661,047 shares during the period. TimesSquare Capital Management LLC boosted its stake in Repligen Corporation by 35.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,970,725 shares of the biotechnology company’s stock valued at $69,370,000 after buying an additional 512,300 shares during the period. William Blair Investment Management LLC boosted its stake in Repligen Corporation by 49.8% in the second quarter. William Blair Investment Management LLC now owns 1,058,976 shares of the biotechnology company’s stock valued at $43,884,000 after buying an additional 352,045 shares during the period. Norges Bank bought a new stake in Repligen Corporation during the fourth quarter valued at approximately $8,527,000. Finally, Macquarie Group Ltd. boosted its stake in Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock valued at $9,852,000 after buying an additional 264,659 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Earnings History and Estimates for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.